Tempest Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TPST Nasdaq 2836 www.tempesttx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tempest Therapeutics, Inc.

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - Nov 26th, 2025 2:05 pm
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - Nov 25th, 2025 6:00 am
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 - Nov 19th, 2025 7:00 am
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 5th, 2025 6:30 am
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer - Aug 13th, 2025 6:00 am
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 11th, 2025 2:12 pm
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China - Jun 30th, 2025 6:00 am
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - Jun 11th, 2025 6:00 am
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC - Jun 5th, 2025 6:00 am
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - May 13th, 2025 2:28 pm
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - Apr 28th, 2025 2:05 pm
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - Apr 21st, 2025 6:00 am
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value - Apr 9th, 2025 2:30 pm
Tempest Reports Year End 2024 Financial Results and Provides Business Update - Mar 27th, 2025 2:10 pm
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Mar 25th, 2025 2:30 pm
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) - Mar 13th, 2025 6:00 am
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma - Feb 10th, 2025 6:00 am
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 7th, 2025 2:30 pm